High-Dose Chemotherapy and Autologous Stem Cells Transplantation for Relapsed/Refractory Hodgkin’s Lymphoma. Is There an Equal Right to Life?

Aim. Hodgkin’s lymphoma (HL) patients with primary refractory (PRef) course of disease or relapses refractory to the previous 2nd line therapy (RRel) often are not given high-dose chemotherapy with autologous stem cell support (ASCS), and this refuse is motivated by its poor efficacy and high toxici...

Полное описание

Библиографические подробности

Главные авторы:	N. V. Zhukov, A. G. Rumyantsev, A. L. Uss, N. F. Milanovich, V. V. Ptushkin, B. V. Afanasyev, N. B. Mikhaylova, V. B. Larionova, E. A. Demina, E. E. Karamanesht, N. G. Tyurina, M. A. Vernyuk, A. D. Kaprin
Формат:	Artigo
Язык:	Russo
Опубликовано:	Practical Medicine Publishing House 2014-07-01
Серии:	Клиническая онкогематология
Предметы:	hodgkin’s lymphoma high-dose chemotherapy autologous hematopoietic stem cells transplantation primary resistance resistant relapse
Online-ссылка:	https://bloodjournal.ru/index.php/coh/article/view/616
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!